Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Published clinical evaluations documented in the New England Journal of Medicine demonstrate how multi-pathway activation modulates glucose homeostasis, hepatic lipid clearance, and metabolic rate in physiological models
After 10 years of treatment, the incidence of MALE was significantly lower in the GLP-1RAs group than in the non-GLP-1RAs group (Monfeuga et al., 2024)
This has direct implications for semaglutide users concerned about skin elasticity during weight loss
All pretty positive stuff really ( Click here for a very good OPEN ACCESS review of the GLP-1-related Parkinsons research field)
.webp)
